Interaction between posaconazole & flucloxacillin in a lung transplant patient: decrease in plasma exposure of posaconazole & possible undertreatment of invasive aspergillosis: case report

Introduction Triazole antifungals like voriconazole, posaconazole, and isavuconazole are used to treat invasive fungal infections like pulmonary aspergillosis. Triazoles inhibit cytochrome P450 enzymes (CYP450) and cause fungal cell death by…

Continue ReadingInteraction between posaconazole & flucloxacillin in a lung transplant patient: decrease in plasma exposure of posaconazole & possible undertreatment of invasive aspergillosis: case report

Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant

Introduction Despite advancements in antifungal therapy over the last two decades, invasive fungal infections (IFIs) continue to be a major cause of morbidity and mortality among immunocompromised patients, particularly if…

Continue ReadingReal-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant

An Update on Eight “New” Antibiotics against Multidrug-Resistant Gram-Negative Bacteria

Introduction Gram-negative bacteria cause two-thirds of infections in intensive care units (ICUs), and antibiotic resistance among these bacteria is a serious issue. Several multidrug-resistant Gram-negative bacteria, including carbapenem-resistant Acinetobacter baumannii,…

Continue ReadingAn Update on Eight “New” Antibiotics against Multidrug-Resistant Gram-Negative Bacteria

Bioresponsive micro-to-nano albumin-based systems for targeted drug delivery against complex fungal infections

Introduction Cryptococcus neoformans is a life-threatening invasive fungal disease. It is more than merely a multi-organ infection; the fungus' intracellular survival and extracellular proliferation play essential roles in the pathophysiology…

Continue ReadingBioresponsive micro-to-nano albumin-based systems for targeted drug delivery against complex fungal infections

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Introduction Candida glabrata is a new Candida species that causes infections ranging from minor to life-threatening systemic illness. Echinocandins and azoles are commonly employed as first-line therapy to treat C.…

Continue ReadingIbrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Prolonged versus intermittent Beta-lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients

Background The prolonged β-lactam infusion strategy has emerged as the standard treatment for sepsis or septic shock despite its unknown efficacy. This study aimed to assess the efficacy of prolonged…

Continue ReadingProlonged versus intermittent Beta-lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients